Key result
The minor G allele of the ANP genetic variant rs5068 is associated with a lower prevalence of metabolic syndrome and hypertension compared to the major allele.
Why the study?
Does the minor G allele of the ANP genetic variant rs5068 improve cardiometabolic phenotype in a Mediterranean population?
Cross-Sectional (n=804)
No
Does the minor G allele of the ANP genetic variant rs5068 improve cardiometabolic phenotype in a Mediterranean population?
The minor G allele of the ANP genetic variant rs5068 is associated with a favorable cardiometabolic phenotype, including lower blood pressure, BMI, and prevalence of hypertension and metabolic syndrome, in a Mediterranean population.
Answers are grounded in this paper and cite their sources.
Supports cardiometabolic benefit of ANP rs5068 G allele in Mediterranean cohorts; leaves open causal effects and clinical utility pending randomized data.
OBJECTIVE: We hypothesized that the minor allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a general Mediterranean population. RESEARCH DESIGN AND METHODS: We genotyped a random sample of the residents of Ventimiglia di Sicilia, Sicily, for rs5068. RESULTS: Genotype frequencies of rs5068 are AA, 93.5%; AG, 6.4%; and GG, 0.1%. All subsequent analyses are AA versus AG+GG. After adjusting for age and sex, the minor G allele is associated with lower BMI (estimate [SE]: -1.7 kg/m(2) [0.8], P = 0.04). In the AG+GG group, males with HDL cholesterol levels <40 mg/dL are less frequent (P = 0.05) and obesity tends to be less prevalent (P = 0.07). Importantly, the G allele is associated with a lower prevalence of metabolic syndrome (P = 0.02). After adjusting for BMI, the above associations were attenuated. Independently of age, sex, and BMI, the minor allele is also associated with lower systolic blood pressure (-6.0 mmHg [2.5], P = 0.02) and lower prevalence of hypertension (odds ratio 0.41 [95% CI 0.20-0.83], P = 0.01). CONCLUSIONS: The association between the minor allele of rs5068 and a favorable cardiometabolic phenotype that we previously reported in a U.S. population is now replicated in a Mediterranean population in which the G allele of rs5068 is associated with lower blood pressure, BMI, and prevalence of hypertension and metabolic syndrome. These findings may lead to a diagnostic strategy to assess cardiometabolic risk and lay the foundation for the future development of an ANP or ANP-like therapy for metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Cannone et al. (2013) conducted a cross-sectional in Cardiometabolic phenotype (n=804). Minor G allele of the ANP genetic variant rs5068 vs. AA genotype (major allele homozygotes) was evaluated on Prevalence of metabolic syndrome (OR 0.42, 95% CI 0.20-0.89, p=0.02). The minor G allele of the ANP genetic variant rs5068 is associated with a lower prevalence of metabolic syndrome and hypertension compared to the major allele.
Synapse has enriched 10 related papers. Consider them for comparative context: